WO1982000643A1 - Substituted oxiranecarbonic acids,preparation and pharmaceutical utilisation thereof - Google Patents

Substituted oxiranecarbonic acids,preparation and pharmaceutical utilisation thereof Download PDF

Info

Publication number
WO1982000643A1
WO1982000643A1 PCT/EP1981/000136 EP8100136W WO8200643A1 WO 1982000643 A1 WO1982000643 A1 WO 1982000643A1 EP 8100136 W EP8100136 W EP 8100136W WO 8200643 A1 WO8200643 A1 WO 8200643A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
hydrogen atom
integer
acids
oxirane
Prior art date
Application number
PCT/EP1981/000136
Other languages
German (de)
English (en)
French (fr)
Inventor
Gulden Lomberg Gmbh Byk
K Eistetter
G Ludwig
H Wolf
E Rapp
Original Assignee
Byk Gulden Lomberg Chem Fab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Byk Gulden Lomberg Chem Fab filed Critical Byk Gulden Lomberg Chem Fab
Publication of WO1982000643A1 publication Critical patent/WO1982000643A1/en
Priority to DK183882A priority Critical patent/DK171890B1/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C29/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
    • C07C29/132—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group
    • C07C29/136—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group of >C=O containing groups, e.g. —COOH
    • C07C29/147—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group of >C=O containing groups, e.g. —COOH of carboxylic acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C29/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
    • C07C29/36—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring increasing the number of carbon atoms by reactions with formation of hydroxy groups, which may occur via intermediates being derivatives of hydroxy, e.g. O-metal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
    • C07C43/14—Unsaturated ethers
    • C07C43/17—Unsaturated ethers containing halogen
    • C07C43/174—Unsaturated ethers containing halogen containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
    • C07C43/14—Unsaturated ethers
    • C07C43/178—Unsaturated ethers containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/225—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/257—Ethers having an ether-oxygen atom bound to carbon atoms both belonging to six-membered aromatic rings
    • C07C43/29—Ethers having an ether-oxygen atom bound to carbon atoms both belonging to six-membered aromatic rings containing halogen

Definitions

  • the invention relates to phen (alk) oxy-substituted oxirane carboxylic acids, processes for their production, their use and medicaments containing them.
  • Phenoxymethyloxiranes e.g. 2- (4-nitrophenoxymethyl) oxirane
  • phenyloxy rancarboxylic acid esters e.g. 2-phenyloxirane-2-carboxylic acid ethyl ester, i.a. used in the context of an investigation into the ability of substituted three-ring compounds to serve as substrates or inhibitors for guinea pig liver microsomal epoxide hydrase [F. Oesch et al. , Biochem. 10 (1971) No. 26, 4858-66].
  • Substituted glycidic acid derivatives are described in US Pat. No.
  • the invention relates to phen (alk) oxy-substituted oxirane carboxylic acids of the general formula I.
  • R 1 represents a hydrogen atom, a halogen atom, a lower alkyl group, a lower alkoxy group, a nitro group or a trifluoromethyl group,
  • R 2 has one of the meanings of R 1 ,
  • R 3 represents a hydrogen atom or a lower alkyl group
  • Y is the grouping -O- (CH 2 ) m -, m 0 or an integer from 1 to 4 and n is an integer from 2 to 8, the sum of m and n being an integer from 2 to 8, and the salts of the carboxylic acids.
  • Straight-chain or branched alkyl radicals having 1 to 4 carbon atoms are suitable as lower alkyl groups.
  • Straight-chain alkyl radicals are, for example, the methyl, ethyl, n-propyl and n-butyl radical, of which those with 1 and 2 carbon atoms are preferred.
  • Branched alkyl radicals are, for example, the isopropyl, isobutyl and sec-butyl radical, of which the one with 3 carbon atoms is preferred.
  • Both straight-chain and branched lower alkyl groups are suitable as alkyl radicals of lower alkoxy groups. The methoxy group is preferred as the lower alkoxy group.
  • Halogen atoms are fluorine, chlorine and bromine atoms, of which fluorine, in particular chlorine, are preferred.
  • the substituents R 1 and R 2 of the phenyl ring are preferably in the meta or para position to the (alk) oxyalkyleneoxirane carboxylic acid residue.
  • Suitable salts are salts with inorganic and organic bases. Salts which are not pharmacologically acceptable are prepared by methods known per se in pharmacological, i.e. converted to biological, compatible salts which are preferred among the salts according to the invention.
  • the cations of the alkali metals, alkaline earth metals or earth metals are mainly used as cations for salt formation, but the corresponding cations of organic nitrogen bases, such as amines, aminoalkanols, amino sugars, basic amino acids, etc., are also used.
  • One embodiment of the invention is phen (alk) oxy-substituted oxirane carboxylic acids of the general formula I *
  • R 1 * and R 2 * are meta or para and R 1 * is a hydrogen atom, a chlorine atom, a methyl group, a methoxy group, a nitro group or a trifluoromethyl group, R 2 * is a hydrogen atom or a chlorine atom,
  • R 3 * is a hydrogen atom or a lower alkyl group
  • Y * is the grouping -O- (CH 2 ) m * -, m * 0 or 1 and n * is an integer from 3 to 7, the sum of m * and n * being an integer from 3 to 7, as well as the salts of the carboxylic acids.
  • a preferred embodiment of the invention are phenoxy-substituted oxirane carboxylic acids of the general formula 1 **
  • R 1 ** is meta or para and R 1 ** is a hydrogen atom, a chlorine atom or a trifluoromethyl group
  • R 2 ** is a hydrogen atom
  • R 3 ** is a hydrogen atom, a methyl group or an ethyl group
  • n ** is an integer from 4 to 6
  • the pharmacologically tolerable salts of carboxylic acids with inorganic or organic bases is an integer from 4 to 6
  • Representatives of the compounds according to the invention are, for example, ethyl 2- [2- (2-phenylethoxy) ethyl] oxirane-2-carboxylate, 2- ⁇ 2- [2- (4-chlorophenyl) ethoxy] ethyl ⁇ oxirane 2-carocanoic acid isopropyl ester, 2- ⁇ 2- [2- (4-fluorophenyl) ethoxy] ethyl ⁇ oxirane-2-carboxylic acid methyl ester, 2- ⁇ 2- [2- (3- ⁇ rifluoromethylphenyl) -etnoxy] ethyl ⁇ - butyl oxirane-2-carboxylic acid,
  • the phen (alk) oxy-substituted oxirane carboxylic acids of the general formula I or of the embodiments I * and I ** have a chirality center.
  • the invention therefore includes the racemates and the enantiomers as well as their mixtures.
  • the compounds according to the invention have valuable pharmacological properties which make them commercially usable. They are hypoglycemic and hypoketonemic.
  • pre-diabetic conditions for preventing the manifestation of diabetes overt diabetes, e.g. Adult diabetes, unstable diabetes in adolescents and all pathological conditions that are associated with pathologically increased ketone body production.
  • the counterpoint of the invention is therefore also a method for combating the diseases caused by application of the compounds according to the invention.
  • the invention also relates to the use of the compounds according to the invention in combating the specified diseases.
  • the invention further relates to medicaments which contain one or more of the phen (alk) oxy-substituted oxirane carboxylic acids of the general formula I.
  • R 1 is a hydrogen atom, a halogen atom, a lower alkyl group, a
  • R 2 has the meanings of R 4 ,
  • R 3 is a hydrogen atom or a lower alkyl group
  • Y is the grouping -O- (CH 2 ) m -, m 0 or an integer from 1 to 4 and n is an integer from 2 to 8, the sum of m and n being an integer from 2 to 8, and / or contain the pharmacologically acceptable salts of the acids with inorganic or organic bases.
  • Refinements of the medicaments are those which contain phen (alk) oxy-substituted oxirane carboxylic acids of the refinements I * or I ** and / or the pharmacologically tolerable salts of the acids with inorganic or organic bases.
  • the invention also relates to the use of the compounds according to the invention for the production of medicaments for combating the specified diseases.
  • the pharmaceuticals are manufactured according to methods known per se.
  • the new compounds can be used as medicaments as such or, if appropriate, in combination with suitable pharmaceutical carriers. If the new pharmaceutical preparations contain pharmaceutical carriers in addition to the active ingredients, the active ingredient content of these mixtures is 1 to 95, preferably 15 to 85 percent by weight of the total mixture.
  • the active ingredients can be used in any form, for example systemically, in the human medical field, provided that the formation or maintenance of sufficient blood or tissue levels of active ingredients is ensured. This can be achieved, for example, by oral or parenteral administration in suitable doses.
  • the pharmaceutical preparation of the active ingredient is advantageously in the form of unit doses which are tailored to the desired administration.
  • a unit dose can be, for example, a tablet, a dragee, a capsule, a suppository or a measured volume of a powder, a granulate, a solution, an emulsion or a suspension.
  • unit dose is understood to mean a specific unit which contains an individual amount of the active ingredient in combination with a pharmaceutical carrier, the active ingredient content of which corresponds to a fraction or a multiple of an individual therapeutic dose.
  • a single dose preferably contains the amount of active ingredient which is administered in one application and which usually corresponds to a whole, a half, a third or a fourth of the daily dose. If only a portion, such as half or a quarter, of Ger unit dose is required for a single therapeutic administration, the unit dose is advantageously divisible, for example in the form of a tablet with a score line.
  • the pharmaceutical preparations according to the invention contain when they are in unit nozzles and for application, e.g. about 2 to 200 mg, advantageously 10 to 100 mg and in particular 20 to 60 mg of active ingredient.
  • a single dose contains the active ingredient or ingredients in amounts of about 0.05 to about 10, preferably 0.1 to 5, in particular 0.3 to 1 mg / kg body weight.
  • parenteral treatment e.g. Similar doses can be used for intravenous or intramuscular application. With this therapy, about 0.3 to 1 mg of active ingredient / kg body weight is apolished. If necessary, the dose can be increased to 0.3 to 15, in particularly acute cases to 0.3 to 30 mg of active ingredient / kg body weight.
  • the therapeutic treatment of the pharmaceutical preparation is generally carried out at fixed times, such as 1 to 4 times a day, for example after meals and / or in the evening. at Medication takes place at acute times at varying times. Under certain circumstances, it may be necessary to deviate from the doses mentioned, depending on the type, body weight and age of the individual to be treated, the type and severity of the disease, the type of preparation and administration of the drug, and the period or interval within which the administration takes place. In some cases it may be sufficient to use less than the above-mentioned amount of active ingredient, while in other cases the amount of active ingredient mentioned above must be exceeded. The determination of the optimal dosage and required
  • the specialist applies the active substances on the basis of his specialist knowledge.
  • the pharmaceutical preparations generally consist of the active compounds according to the invention and non-toxic, pharmaceutically acceptable pharmaceutical carriers which are used as admixtures or diluents in solid, semi-solid or liquid form or as enveloping agents, for example in the form of a capsule, a tablet cover, a bag or another container for the therapeutically active ingredient.
  • a carrier can e.g. serve as a mediator for the medication uptake by the body, as a formulation aid, as a sweetener, as a flavor correcting agent, as a color or as a preservative.
  • Tablets, dragees, hard and soft capsules e.g. come from gelatin, dispersible powder, granules, aqueous and oily suspensions, emulsions or solutions.
  • Tablets can contain inert diluents, for example calcium carbonate, calcium phosphate, sodium phosphate or xylitol; Granulating and distributing agents, for example calcium phosphate or alginates; Binders, for example starch, gelatin or acacia; and lubricants, such as aluminum or magnesium stearate, talc or silicone oil. You can also use a Be provided cover, which can also be such that a delayed dissolution and absorption of the drug in the gastrointestinal tract and thus, for example, better tolerance, protracting or retardation is achieved.
  • Gelatin capsules can contain the drug mixed with a solid diluent, eg calcium carbonate or kaolin, or an oily diluent, eg paraffinol.
  • Aqueous suspensions can include suspending agents, e.g. Sodium carboxymethyl cellulose, methyl cellulose, hydroxypropyl cellulose, sodium alginate, poly vinyl pyrrolidone, gum tragacanth or acacia; Dispersing and wetting agents, e.g. Polyoxyethylene stearate, heptadecaethylene xycetanol, poly cxyethylene sorbitol monooleate, polyoxyethylene sorbitan monooleate or lecithin; Preservatives, e.g. Methyl or propylhy ⁇ roxybenzoates; Gescimacks medium; Sweeteners, e.g. Saccharin, sodium cyclamate.
  • suspending agents e.g. Sodium carboxymethyl cellulose, methyl cellulose, hydroxypropyl cellulose, sodium alginate, poly vinyl pyrrolidone, gum tragacanth or acacia
  • Dispersing and wetting agents e.g
  • Oily suspensions can e.g. Paraffinol and thickeners, such as beeswax, hard paraffin or cetyl alcohol, contain; also sweeteners, flavoring agents and antioxidants.
  • Paraffinol and thickeners such as beeswax, hard paraffin or cetyl alcohol, contain; also sweeteners, flavoring agents and antioxidants.
  • the drugs can be mixed with dispersing, wetting and suspending agents, e.g. the above, as well as with sweeteners, flavoring agents and colorants.
  • Emulsions can e.g. Paraffinol in addition to emulsifiers such as acacia, tragacanth, phosphatides, sorbitan monooleate, polyoxyethylene sorbitan monooleate, and sweeteners and flavoring agents.
  • emulsifiers such as acacia, tragacanth, phosphatides, sorbitan monooleate, polyoxyethylene sorbitan monooleate, and sweeteners and flavoring agents.
  • Sterile injectable aqueous suspensions, isotonic saline solutions or other solutions which can contain dispersing or wetting agents and / or pharmacologically acceptable diluents, for example propylene or butylene glycol, are used for parenteral use of the medicinal substances.
  • the active ingredient (s) can also be formulated in microencapsulated form with one or more of the specified carriers or additives.
  • the pharmaceutical preparations can furthermore group one or more pharmacologically active constituents of other medicament groups, such as antidiabetic agents (sulfonamides, sulfonylureas, etc.) ), e.g. Carbutamide, tolbutamide, chlorpropamide, glibenclamide, glibornuride, glisoxepid, gliquidon, glymidine or hypolipidemics, such as nicotinic acid and its derivatives and salts, contain.
  • antidiabetic agents sulfonamides, sulfonylureas, etc.
  • Another object of the invention is a process for the preparation of phen (alk) oxy-substituted oxirane carboxylic acids of the general formula I.
  • R 1 represents a hydrogen atom, a halogen atom, a lower alkyl group, a lower alkoxy group, a nitro group or a trifluoromethyl group,
  • R 2 has one of the meanings of R 1 , R 3 represents a hydrogen atom or a lower alkyl group,
  • Y is the grouping -O- (CH 2 ) m -, m O or an integer from 1 to 4 and n is an integer from 2 to 8, the sum of m and n being an integer from 2 to 8, and the salts of the acids, characterized in that a substituted ⁇ -methylene carboxylic acid of the general formula II in which R 1 , R 2 , R 3 , Y and n have the meaning given above, oxidized and, if appropriate, subsequently saponifying the lower alkyl esters obtained or converting the acids obtained into the salts or lower alkyl esters.
  • the ⁇ -methylene carboxylic acids II are oxidized under the conditions known to the person skilled in the art for the oxidation of carbon-carbon double bonds to epoxides.
  • suitable oxidizing agents are peroxo compounds, such as hydrogen peroxide, peracetic acid, trifluoroperacetic acid, 3, 5-dinitroperbenzoic acid, preferably m-chloroperbenzoic acid, per maleic acid.
  • the reaction is conveniently in inert solvents, z. B. aromatic or chlorinated hydrocarbons such as benzene, toluene, dichloromethane, chloroform.
  • the reaction temperatures are between 0 ° and the boiling point of the solvent, before being between 20 ° and 70 ° C.
  • the lower alkyl esters are saponified in a manner known per se. It is carried out, for example, with an aqueous or alcoholic (e.g. ethanolic) alkali metal hydroxide (e.g. potassium hydroxide) solution at room temperature, optionally with the addition of an inert diluent, such as dioxane, tetrahydrofuran or toluene.
  • an aqueous or alcoholic (e.g. ethanolic) alkali metal hydroxide (e.g. potassium hydroxide) solution at room temperature
  • an inert diluent such as dioxane, tetrahydrofuran or toluene.
  • the inorganic or organic base whose salt is desired is used as the alkaline reactant.
  • Base for example sodium hydroxide or sodium ethanolate, or easily soluble salts converted into poorly soluble salts by double reaction, or any salts converted into pharmacologically acceptable salts.
  • lower alkanols are treated with lower alkanols in the presence of strong acids, such as sulfuric acid, D-toluenesulfonic acid, or with acidic ion exchangers under conditions in which no decarboxylation takes place, or with dialkyl sulfates or alkyl halides in the presence of diazabicycloundecene or diazabicyclonones in inert solvents, such as benzene.
  • strong acids such as sulfuric acid, D-toluenesulfonic acid, or with acidic ion exchangers under conditions in which no decarboxylation takes place
  • dialkyl sulfates or alkyl halides in the presence of diazabicycloundecene or diazabicyclonones in inert solvents, such as benzene.
  • diazabicycloundecene or diazabicyclonones inert solvents
  • the compounds of the general formula I are normally obtained in the form of racanic mixtures which are separated into the enanticmeres by known processes.
  • the racemate is converted into diasterecmers using an optically active cleaving agent, which are then separated by selective crystallization and converted into the corresponding optical isomers.
  • optically active splitting agents e.g. optically active bases, such as l- and d-1-phenylethylamine, cinchonidine or d-ephedrine, from which salts of the acids of the general formula I, or optically active alcohols, such as bomeol or mentnol, from which esters of the acids of the general formula I are prepared become.
  • optically active sorbents It is also possible to break down rac aric mixtures into the optical isomers by chromatography using optically active sorbents.
  • the ⁇ -methylene carboxylic acids II are first reacted with an optically active cleaving agent, e.g. Borneol or Mentnol, the products obtained are oxidized to the corresponding diastereomer mixtures of the oxirane carboxylic acid esters, from which the optical isomers of the acids I are then obtained in a conventional manner.
  • an optically active cleaving agent e.g. Borneol or Mentnol
  • R 1 * , R 2 * , R 3 * , Y * and n * or R 1 ** , R 2 ** , R 3 ** , Y ** and n ** have the meaning given above.
  • ⁇ -methylene caroic acids of the general formulas II, II * and II ** are known to be prepared according to known methods. They are valuable intermediates for the synthesis of oxirane carboxylic acids I, I * and I **
  • ⁇ -methylenecarboxylic acids II and their salts are prepared, for example, in analogy to H. Stetter and H. Kuhlmann [Synthesis 1979, 29] by reacting malonic acid semiesters of the general formula III
  • R 1 , R 2 , Y and n have the meaning given above and R 4 is a lower alkyl group, with formaldehyde in pyridine in the presence of secondary amines, preferably piperidine, and optionally subsequent saponification of the Nieceralkylester obtained or conversion into the salts.
  • the best malonic acid III is prepared by methods known to those skilled in the art, for example by reacting dialkyl malenates IV with phen (alk) oxyalkyl compounds V and partial hydrolysis of maleated malonic acid diesters VI according to the following scheme
  • R 1 , R 2 , R 4 , Y and n have the meaning given above and X is a
  • Escape group e.g. represents a chlorine or sroma atom, a mesyloxy or a p-toluenesulfonyloxy group.
  • R 1 * , R 2 * , Y * and n * or R 1 ** , R 2 ** , Y ** and n ** have the meanings given above;
  • R 4 * is a lower alkyl group, R 4 ** is a methyl or ethyl group and X * or X ** is a chlorine or bromine atom, a mesyloxy or a p-toluenesulfonyloxy group.
  • V ** are produced by known processes, e.g. analogously to J.Augstain et al. [J.Med.Chera. 8 (1965) 355-367] or J.D. Genzsr et al. [J.Amer. Chen.Soc. 73 (1951) 3159-3162] or Sh. Mamedov et al. [Chem. Abstr. 59 (1963) 4410e and Chem. Abstr. 60 (1964) 5321c].
  • the phen (alk) oxyalkyl compounds V analog Genzer et al.
  • Number from 1 to 4 means.
  • the phenalkyl chlorides VIII are obtained by known processes by reducing the carboxylic acids X and then reacting the resulting ones
  • Number from 1 to 4 means.
  • 166.6 g of 6- (4-methylphenoxy) -2-methylenehexanoic acid ethyl ester [of bp. 132-134 ° C. at 0.1 Torr (13.3 Pa)] are obtained from 254 g of 4- (4-methylphenoxy) -butylmalonic acid ethyl ester, 27.2 g paraformaldehyde, 260 ml pyridine and 9 ml piperidine.
  • Example 1a The procedure described in Example 1a gives 46.9 g of the title compound [as a colorless oil, purified by chromatography on silica gel (mobile phase: petroleum ether / methylene chloride 1: 1); R f 0.6 in thin layer chromatography on silica gel with petroleum ether / ethyl acetate / acetic acid (80:20: 3)] from 48.3 g of 2-methylene-6- (3-trifluoromethylphenoxy) -hexanoic acid ethyl ester and 62 g of m-chloroperbenzoic acid in 950 ml of methylene chloride. b) 2-methylene-6- (3-trifluoromethylphenoxy) hexanoic acid ethyl ester
  • Example 1c The procedure described in Example 1c gives 90.7 g of ethyl 4- (3-trifluoromethylphenoxy) butylmalonic acid (as a yellowish, viscous oil) from 117 g of diethyl 4- (3-trifluoromethylphenoxy) butylmalonate and 20.5 g of potassium hydroxide in 650 ml of ethanol.
  • Ethyl 2- (3-phenoxypropyl) oxirane-2-carboxylate a) Ethyl 2- (3-phenoxypropyl) oxirane-2-carboxylate According to the procedure described in Example 1a), 14.0 g of the title compound [are obtained as an almost colorless oil , purified by chromatography on a silica gel column (eluent: methylene chloride); R f 0.4 in thin layer chromatography on a silica gel plate with petroleum ether / ethyl acetate / acetic acid (80: 20: 3)] from 70.3 g of 2-methylene-5-phenoxyvaleric acid ethyl ester and 124.3 g of m-chloroperbenzoic acid in
  • Title compound [as a colorless oil, bp 164 ° C at 0.2 torr (26.6 Pa)] from 15.0 g of ethyl 8- (4-chlorophenoxy) -2-methylenoctanoate and 14.2 g of m-chloroperbenzoic acid in 50 ml of methylene chloride.
  • Example 8 2- [3- (4-nitrophenoxy) propylj-oxirane-2-carboxylic acid ethyl ester a) 2- [3- (4-nitrophenoxy) propyl] oxirane-2-carboxylic acid ethyl ester obtained according to the procedure described in Example 1a) one 3.8 g
  • Ethyl 2- [3- (4-nitrophenoxy) propyl] oxirane-2-carboxylate (as a yellow oil which solidifies after standing for a long time, mp 60 °) from 10 g of 2-methylene-5- (4-nitrophenoxy) - ethyl valerate and 10.5 g m-chloroperbenzoic acid in 50 ml methylene chloride.
  • Example 1b The procedure described in Example 1b) gives 61 g of ethyl 2-methylene-5- (4-nitrophenoxy) valerate [as a yellow oil, bp. 167-170 ° at 0.005 torr (0.7 Pa)], from 89 g 3 - (4-Nitrophenoxy) -propyl mal ononate, 10.8 g paraformaldehyde, 54 ml pyridine and 4 ml Piperi din. c) 3- (4-Nitrophenoxy) propylmalonic acid ethyl ester
  • Ethyl 2- (5-phenoxypentyl) -oxirane-2-carboxylate a) Ethyl 2- (5-phenoxypentyl) -oxirane-2-carboxylate According to the procedure described in Example 1a), 2.15 g of the title compound [purified as a colorless oil are obtained by chromatography on silica gel (mobile phase: petroleum ether / ethyl acetate 9: 1); Thin layer chromatography on silica gel: R f 0.4] from 10 g of 2-methylene-7-phenoxyheptanoic acid ethyl ester and 11.6 g of m-chloroperbenzoic acid in 50 ml of methylene chloride. 4.7 g of the starting compound are recovered. b) Ethyl 2-methylene-7-phenoxyheptanoate
  • 5- (4-Chlorophenoxy) pentylmalonic acid diethyl ester [bp 160-161 ° at 0.01 Torr (1.3 Pa)] from 212.6 g of 5- (4-chlorophenoxy) pentyl bromide, 185.8 g of malonic acid diethyl ester and a solution of 17.7 g sodium in 1.25 T ethanol.
  • Example 1a According to the procedure described in Example 1a), 7.2 g of the title compound [as an almost colorless OT, purified by chromatography on KieseTgeT (eluent: petroleum ether / ethyl acetate 9: 1)] are obtained from 26 g of 5-benzyloxy-2-methylenevaTerian acid ethyl ester and 48 g m-chloroperbenzoic acid in 200 ml methylene chloride. b) Ethyl 5-benzyloxy-2-methylenevalerate According to the procedure described in Example 1b), 30.1 g are obtained
  • Ethyl 2- [2- (3-phenylpropyloxy) ethyl] oxirane-2-carboxylate is obtained by the procedure described in Example 1a) 6.6 g of the title compound as a colorless oil with a bp of 142 ° at 0.15 Torr (20 Pa) [purification by chromatography on silica gel (mobile phase: petroleum ether / ethyl acetate 9: 1)] from 18.0 g of 2-methylene-4 - (3-phenylpropyloxy) - butyric acid ethyl ester and 22 g m-chloroperbenzoic acid in 150 ml methylene chloride.
  • Ethyl 2- [2- (4-chlorobenzyloxy) ethyl] oxirane-2-carboxylate is obtained by the procedure described in Example 1a) 6.2 g of the title compound of bp 130-135 ° at 0.05 torr (7 Pa) from 10.3 g of 4- (4-chlorobenzyloxy) -2-methylene butyric acid ethyl ester and 13 g of m-chloroperbenzoic acid in 100 ml of methylene chloride.
  • Ethyl 2- [4- (4-methylphenoxy) butyl] oxirane-2-carboxylate As an alternative to Example 2, the title compound is obtained as follows: 17.6 g of freshly ground maleic anhydride are added to a solution of 5.0 prepared at 0 ° g of 85% hydrogen peroxide in 100 ml of methylene chloride at once, the temperature falling from 0 to -5 °. After stirring for 1 hour in an ice bath, the solution of permaleic acid is mixed with 17.0 g of ethyl 6- (4-methylphenoxy) -2-methylenehexanoate in 50 ml of methylene chloride and then heated to boiling under reflux for 16 hours.
  • the precipitated maleic acid is filtered off, stirred for two hours with 150 ml of saturated sodium hydrogen carbonate solution, first with ice cooling, then at room temperature, the organic phase is separated off and the stirring is repeated once. After renewed phase separation, the organic phase is stirred with 30 g of solid sodium hydrogen sulfite (1 hour), (peroxide detection negative), filtered, completely concentrated and the residue is distilled. 10.5 g of the title compound are obtained as light yellow 01, which is purified by chromatography on a silica gel column (mobile phase: petroleum ether / methylene chloride 1: 1). Rf: 0.4 in thin layer chromatography on a silica gel plate with chloroform.
  • Example 1 Mixture for ampoules 100 g of 2- [5- (4-chlorophenoxy) pentyl] oxirane-2-carboxylic acid are distilled in about 8 liters of aqua. dissolved with the addition of the equivalent amount of sodium hydroxide solution. The solution is adjusted to pH 7.0-0.5 and with aqua bi dest. made up to 10 liters. Then it is sterile filtered and filled into aseptic conditions in 2 ml ampoules.
  • 1000 capsules with an active ingredient content of 25 mg are prepared as follows: 25 g of ethyl 2- [4- (3-chlorophenoxy) butyl] oxirane-2-carboxylate are dissolved in 100 ml of methylene chloride. The solution is mixed well with 75 g of micronized silica. The mixture is evaporated to dryness and then filled into hard gelatin capsules.
  • 10000 capsules with an active ingredient content of 25 mg are produced as follows:
  • Example 6 Tablets with an active ingredient content of 25 mg are produced as follows:
  • Example Aa The procedure described in Example Aa gives 10.3 g of 3- (3-trifluoromethylphenyl) propyl chloride (oil) from 12 g of 3- (3-trifluoromethylphenyl) propanol-1 and 10 g of thionyl chloride.
  • the phen (alk) oxy-substituted oxirane carboxylic acids of the general formula I according to the invention lower the blood glucose level and the blood level of the ketone body, whereby their chemical structure and their effectiveness fundamentally differ from pancreatic, betacytotropic substances (e.g. sulfonylureas) due to their extrapancreatic effect distinguish and prove to be superior to extrapancreatic commercial products (e.g. buformin and phen formin).
  • pancreatic, betacytotropic substances e.g. sulfonylureas
  • A is the active ingredient dose (mg / kg), which is 50% of the animals
  • Control group causes, in column B, the one in 50% of the animals
  • the pharmacological properties were determined using the following methods:
  • ED values are calculated from the dose-response relationship by linear or loglinear regression.
  • the toxicity studies are carried out on female NMRI mice (body weight 22-25 g). The animals (5 animals per dose) receive the food (Altomin ® ) reduced to 50 g / 50 animals and water ad libitum 18 hours before the treatment. Different doses of the substances are administered orally by gavage (volume 10 ml / kg). The observation period is 7 days.
  • the LD 50 ie the dose at which 50% of the animals die, is determined graphically from the dose-response curve.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epoxy Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PCT/EP1981/000136 1980-08-25 1981-08-24 Substituted oxiranecarbonic acids,preparation and pharmaceutical utilisation thereof WO1982000643A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DK183882A DK171890B1 (da) 1980-08-25 1982-04-23 Analogifremgangsmåde til fremstilling af phen(alk)oxyalkyl-substituerede oxirancarboxylsyrer eller derivater deraf og mellemprodukter til anvendelse som udgangsmaterialer ved fremgangsmåden

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CH639780 1980-08-25
CH6397/80 1980-08-25
CH1526/81810306 1981-03-06
CH152681 1981-03-06

Publications (1)

Publication Number Publication Date
WO1982000643A1 true WO1982000643A1 (en) 1982-03-04

Family

ID=25687902

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1981/000136 WO1982000643A1 (en) 1980-08-25 1981-08-24 Substituted oxiranecarbonic acids,preparation and pharmaceutical utilisation thereof

Country Status (16)

Country Link
US (1) US4337267A (forum.php)
EP (1) EP0046590B1 (forum.php)
JP (1) JPS6059914B2 (forum.php)
AU (1) AU549447B2 (forum.php)
CA (1) CA1167050A (forum.php)
DE (1) DE3170608D1 (forum.php)
DK (1) DK171890B1 (forum.php)
ES (1) ES504922A0 (forum.php)
GR (1) GR75741B (forum.php)
IE (1) IE51534B1 (forum.php)
IL (1) IL63627A (forum.php)
NZ (1) NZ198136A (forum.php)
PH (1) PH21847A (forum.php)
PT (1) PT73563B (forum.php)
WO (1) WO1982000643A1 (forum.php)
YU (1) YU206681A (forum.php)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545672A (en) * 1993-02-11 1996-08-13 The University Of Texas System Treatment of insulin resistance and type 2 diabetes mellitus with a thiol protease inhibitor
WO2002079178A1 (de) * 2001-03-30 2002-10-10 Medigene Aktiengesellschaft Verfahren zur herstellung von oxirancarbonsäuren und derivaten davon

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2556496B2 (ja) * 1985-08-02 1996-11-20 ホルスト パウル オットー ヴォルフ 高脂血症の治療のための薬剤
GB2202222B (en) * 1987-03-16 1991-03-27 American Home Prod Fluorooxirane carboxylates
US4788304A (en) * 1987-12-07 1988-11-29 American Home Products Corporation Phospholipase A2 inhibitors
DE3906953A1 (de) * 1989-03-04 1990-09-20 Byk Gulden Lomberg Chem Fab Verfahren zur herstellung optisch reiner oxirancarbonsaeuren
US5556863A (en) * 1993-06-11 1996-09-17 Astra Aktiebolag Compound for gastric acid secretion inhibition
IS4164A (is) * 1993-06-11 1994-12-12 Ab Astra Efnasambönd sem hindra flæði magasýru
JP2000513373A (ja) * 1996-07-02 2000-10-10 ジュウ，サング，スプ オキシランカルボキシル酸誘導体及びその製造方法
KR19980028082A (ko) * 1996-10-21 1998-07-15 김박광 혈당 강하 작용을 갖는 신규 옥시란 카복실산의 유도체, 그 제조방법 및 이를 함유하는 당뇨병 치료제
DE19705718A1 (de) * 1997-02-14 1998-08-20 Horst P O Dr Wolf Neue Oxirancarbonsäuren zur Behandlung des Diabetes Typ 2 und anderer insulinresistenter Zustände
US5932763A (en) * 1997-05-15 1999-08-03 Bayer Corporation Inhibition of matrix metalloproteases by 2-(ω-arolalkyl)-4-biaryl-4-oxobutyric acids
JP2005528322A (ja) * 2001-09-26 2005-09-22 エミスフェアー・テクノロジーズ・インク ジカルボキシラート中間体を経てフェノキシアルカン酸、アルケン酸およびアルキン酸ならびにそれらの塩を調製する方法
WO2004071458A2 (en) * 2003-02-13 2004-08-26 Albert Einstein College Of Medicine Of Yeshiva University REGULATION OF FOOD INTAKE AND GLUCOSE PRODUCTION BY MODULATION OF LONG-CHAIN FATTY ACYL-CoA LEVELS IN THE HYPOTHALAMUS
WO2006041922A2 (en) * 2004-10-08 2006-04-20 Dara Biosciences, Inc. Agents and methods for administration to the central nervous system
WO2006088875A2 (en) * 2005-02-14 2006-08-24 Albert Einstein College Of Medicine Of Yeshiva University Intranasal administration of modulators of hypothalamic atp-sensitive potassium channels
US8741949B2 (en) 2008-06-27 2014-06-03 Meta-Iq Aps Inhibitors of carnitin-palmitoyl-tranferase-1 for the treatment and prevention of disorders caused by delipidation of neural tissue
MX389242B (es) 2015-06-15 2025-03-20 Nmd Pharma As Compuestos para su uso en el tratamiento de trastornos neuromusculares
US10385028B2 (en) 2017-12-14 2019-08-20 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
US11591284B2 (en) 2017-12-14 2023-02-28 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
US11730714B2 (en) 2017-12-14 2023-08-22 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
US11147788B2 (en) 2017-12-14 2021-10-19 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1551078A (en) * 1975-09-22 1979-08-22 Mcneilab Inc Alkyl-substituted glycidates and thioglycidates
EP0025192A2 (de) * 1979-09-07 1981-03-18 Byk Gulden Lomberg Chemische Fabrik GmbH Substituierte Oxirancarbonsäuren, Verfahren zu ihrer Herstellung, ihre Verwendung und sie enthaltende Arzneimittel

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196300A (en) * 1975-09-22 1980-04-01 Mcneilabs, Inc. α-Alkyl-substituted glycidates and thioglycidates
US4132719A (en) * 1978-04-20 1979-01-02 Mcneilab Inc. Dibromoalkylglycidic acid derivatives
US4132720A (en) * 1978-04-20 1979-01-02 Mcneil Laboratories, Inc. Alkenylglycidic acid derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1551078A (en) * 1975-09-22 1979-08-22 Mcneilab Inc Alkyl-substituted glycidates and thioglycidates
EP0025192A2 (de) * 1979-09-07 1981-03-18 Byk Gulden Lomberg Chemische Fabrik GmbH Substituierte Oxirancarbonsäuren, Verfahren zu ihrer Herstellung, ihre Verwendung und sie enthaltende Arzneimittel

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545672A (en) * 1993-02-11 1996-08-13 The University Of Texas System Treatment of insulin resistance and type 2 diabetes mellitus with a thiol protease inhibitor
WO2002079178A1 (de) * 2001-03-30 2002-10-10 Medigene Aktiengesellschaft Verfahren zur herstellung von oxirancarbonsäuren und derivaten davon
US7078543B2 (en) 2001-03-30 2006-07-18 Medigene Aktiengesellschaft Methods for producing oxirane carboxylic acids and derivatives thereof

Also Published As

Publication number Publication date
ES8300730A1 (es) 1982-11-16
JPS57501233A (forum.php) 1982-07-15
PH21847A (en) 1988-03-17
PT73563B (en) 1983-07-14
DK183882A (da) 1982-04-23
EP0046590A3 (en) 1982-04-07
IL63627A (en) 1984-11-30
EP0046590A2 (de) 1982-03-03
YU206681A (en) 1983-10-31
CA1167050A (en) 1984-05-08
ES504922A0 (es) 1982-11-16
JPS6059914B2 (ja) 1985-12-27
EP0046590B1 (de) 1985-05-22
AU549447B2 (en) 1986-01-30
IE51534B1 (en) 1987-01-07
US4337267A (en) 1982-06-29
DE3170608D1 (en) 1985-06-27
NZ198136A (en) 1983-12-16
AU7447581A (en) 1982-03-04
PT73563A (en) 1981-09-01
DK171890B1 (da) 1997-08-04
IE811931L (en) 1982-02-25
GR75741B (forum.php) 1984-08-02
IL63627A0 (en) 1981-11-30

Similar Documents

Publication Publication Date Title
EP0046590B1 (de) Phen(alk)oxy-substituierte Oxirancarbonsäuren, Verfahren zu ihrer Herstellung, ihre Anwendung und sie enthaltende Arzneimittel
DE3047142C2 (de) Basische 1,7,7-Trimethylbicyclo[2,2,1]heptyläther, Verfahren zur Herstellung derselben und diese enthaltende Arzneimittel
DE3026201C2 (forum.php)
EP0025192B1 (de) Substituierte Oxirancarbonsäuren, Verfahren zu ihrer Herstellung, ihre Verwendung und sie enthaltende Arzneimittel
EP0046961B1 (de) Epoxi-cycloalkylalkancarbonsäuren, Verfahren zu ihrer Herstellung, ihre Verwendung sowie sie enthaltende Arzneimittel
EP0041215A2 (de) Imidazoazolalkensäureamide, neue Zwischenprodukte zu ihrer Herstellung, ihre Herstellung und ihre Verwendung in Arzneimitteln
EP0157267A2 (de) Substituierte Benzopyrane, Verfahren zu ihrer Herstellung sowie ihre Verwendung in Arzneimitteln
EP0038343B1 (de) Substituierte oxocarbonsäuren, verfahren zu ihrer herstellung, ihre verwendung und sie enthaltende arzneimittel
DE69014798T2 (de) Thionaphthalen-derivate, verfahren zur herstellung und antiallergisches mittel daraus.
EP0008645A1 (de) Alkoxyphenylpyrrolidone, Verfahren zu ihrer Herstellung und Arzneimittel auf Basis dieser Verbindungen
DE2854877A1 (de) N-substituierte omega-thiobutyramide, verfahren zu ihrer herstellung und sie enthaltende arzneimittel
EP0071175B1 (de) Phenylalkyloxirancarbonsäuren, Verfahren zu ihrer Herstellung, ihre Anwendung und sie enthaltende Arzneimittel
EP0006217B1 (de) Substituierte Aminoalkansäuren, ihre Verwendung und Herstellung und sie enthaltende Arzneimittel
EP0072960A2 (de) 1,5-Diphenylpyrazolin-3-on-Verbindungen sowie Verfahren und Zwischenprodukte zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
EP0004522A2 (de) Neue dilignolähnliche Verbindungen, dilignolähnliche Verbindungen zur Verwendung bei der Behandlung von Lebererkrankungen sowie diese enthaltende pharmazeutische Präparate
EP0088323B1 (de) Imidazothiadiazolalkencarbonsäureamide, neue Zwischenprodukte zu ihrer Herstellung, ihre Herstellung und ihre Verwendung in Arzneimitteln
DE3020421A1 (de) Imidazoazolalkensaeureamide, neue zwischenprodukte zu ihrer herstellung, ihre herstellung und ihre verwendung in arzneimitteln
EP0005192B1 (de) Alkylaminopropanolderivate von 3-Alkyl-5-(2-hydroxystyryl)-isoxazolen, Verfahren zu ihrer Herstellung und diese enthaltende therapeutische Mittel
EP0167945B1 (de) Phenylethylaminopropiophenon-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
US4146728A (en) Esters of 2-[4-(4-chlorobenzoyl)-phenoxy-2-methyl-propionic acid with bis-(hydroxyalkylthio)-alkanes
CH638795A5 (en) 1-[3-(3,4,5-trimethoxyphenoxy)-2-hydroxypropyl]-4-arylpiperazine derivatives and process for their preparation
EP0027978B1 (de) Neue Aminoderivate des 5-(2-Hydroxystyryl)-isoxazols, Verfahren zu ihrer Herstellung und diese enthaltende therapeutische Mittel
CA1163644A (en) Process for the preparation of epoxycycloalkylalkanecarboxylic acids
CH495935A (de) Verfahren zur Herstellung von Methylen-substituierten Verbindungen
EP0090353A1 (de) Pyridon-2-derivate, Verfahren zu ihrer Herstellung und sie enthaltende Arzneimittel

Legal Events

Date Code Title Description
AK Designated states

Designated state(s): DK FI HU JP